These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31186753)

  • 21. Stromal fibronectin expression in patients with resected pancreatic ductal adenocarcinoma.
    Hu D; Ansari D; Zhou Q; Sasor A; Said Hilmersson K; Andersson R
    World J Surg Oncol; 2019 Feb; 17(1):29. PubMed ID: 30736807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KIAA1199/CEMIP/HYBID overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
    Koga A; Sato N; Kohi S; Yabuki K; Cheng XB; Hisaoka M; Hirata K
    Pancreatology; 2017; 17(1):115-122. PubMed ID: 28012880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer.
    Javle MM; Gibbs JF; Iwata KK; Pak Y; Rutledge P; Yu J; Black JD; Tan D; Khoury T
    Ann Surg Oncol; 2007 Dec; 14(12):3527-33. PubMed ID: 17879119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma.
    Ueda S; Ogata S; Tsuda H; Kawarabayashi N; Kimura M; Sugiura Y; Tamai S; Matsubara O; Hatsuse K; Mochizuki H
    Pancreas; 2004 Jul; 29(1):e1-8. PubMed ID: 15211117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Fermér C; Nilsson O; Seppänen H; Haglund C
    PLoS One; 2015; 10(6):e0129012. PubMed ID: 26053486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Prognostic Significance of c-MET and EGFR Overexpression in Resected Gastric Adenocarcinomas.
    Paliga A; Marginean H; Tessier-Cloutier B; Purgina B; Jonker D; Marginean EC
    Am J Clin Oncol; 2017 Dec; 40(6):543-551. PubMed ID: 26125303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathological implications of NQO1 overexpression in the prognosis of pancreatic adenocarcinoma.
    Ji M; Jin A; Sun J; Cui X; Yang Y; Chen L; Lin Z
    Oncol Lett; 2017 May; 13(5):2996-3002. PubMed ID: 28521407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.
    Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X
    Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor budding as a prognostic factor in pancreatic ductal adenocarcinoma.
    Petrova E; Zielinski V; Bolm L; Schreiber C; Knief J; Thorns C; Bronsert P; Timme-Bronsert S; Bausch D; Perner S; Keck T; Wellner U
    Virchows Arch; 2020 Apr; 476(4):561-568. PubMed ID: 31786688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Doublecortin and CaM kinase-like-1 as an independent prognostic factor in patients with resected pancreatic carcinoma.
    Nishio K; Kimura K; Amano R; Nakata B; Yamazoe S; Ohira G; Miura K; Kametani N; Tanaka H; Muguruma K; Hirakawa K; Ohira M
    World J Gastroenterol; 2017 Aug; 23(31):5764-5772. PubMed ID: 28883702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Claudin-4 expression predicts survival in pancreatic ductal adenocarcinoma.
    Tsutsumi K; Sato N; Tanabe R; Mizumoto K; Morimatsu K; Kayashima T; Fujita H; Ohuchida K; Ohtsuka T; Takahata S; Nakamura M; Tanaka M
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S491-9. PubMed ID: 21837532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
    Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
    Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression and prognostic significance of lncRNA MALAT1 in pancreatic cancer tissues.
    Liu JH; Chen G; Dang YW; Li CJ; Luo DZ
    Asian Pac J Cancer Prev; 2014; 15(7):2971-7. PubMed ID: 24815433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BTG1 low expression in pancreatic ductal adenocarcinoma is associated with a poorer prognosis.
    Huang Y; Zheng J; Tan T; Song L; Huang S; Zhang Y; Lin L; Liu J; Zheng P; Chen X; Chen X; Ouyang X
    Int J Biol Markers; 2018 May; 33(2):189-194. PubMed ID: 29076521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic impact of the tumor-infiltrating regulatory T-cell (Foxp3
    Hwang HK; Kim HI; Kim SH; Choi J; Kang CM; Kim KS; Lee WJ
    Oncol Lett; 2016 Dec; 12(6):4477-4484. PubMed ID: 28105157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.
    Nahm CB; Turchini J; Jamieson N; Moon E; Sioson L; Itchins M; Arena J; Colvin E; Howell VM; Pavlakis N; Clarke S; Samra JS; Gill AJ; Mittal A
    Eur J Surg Oncol; 2019 Feb; 45(2):218-224. PubMed ID: 30348604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma.
    Seeliger H; Pozios I; Assmann G; Zhao Y; Müller MH; Knösel T; Kreis ME; Bruns CJ
    BMC Cancer; 2018 Oct; 18(1):1049. PubMed ID: 30373552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vimentin Expression in Tumor Microenvironment Predicts Survival in Pancreatic Ductal Adenocarcinoma: Heterogeneity in Fibroblast Population.
    Maehira H; Miyake T; Iida H; Tokuda A; Mori H; Yasukawa D; Mukaisho KI; Shimizu T; Tani M
    Ann Surg Oncol; 2019 Dec; 26(13):4791-4804. PubMed ID: 31583548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor budding is a prognostic factor linked to epithelial mesenchymal transition in pancreatic ductal adenocarcinoma. Study report and literature review.
    Chouat E; Zehani A; Chelly I; Njima M; Maghrebi H; Bani MA; Njim L; Zakhama A; Haouet S; Kchir N
    Pancreatology; 2018 Jan; 18(1):79-84. PubMed ID: 29233500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.